Sanofi Launches Action 2024: Global Employee Shareholder Plan Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, offering approximately 80,000 employees across 56 countries the opportunity to…
Sanofi to Appeal Delaware Court’s Decision on Zantac Sanofi has expressed disappointment with the recent decision by the State of Delaware court and intends to appeal. The company maintains that…
AbbVie announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of risankizumab (SKYRIZI®) for treating…
Imagine a contact lens that reshapes the cornea while you sleep, improving your vision. Picture wearing a contact lens equipped with technology to alleviate the strain from increased digital screen…
IGC Pharma Begins Patient Enrollment for Phase 2 Alzheimer’s Agitation Trial at Neurostudies IGC Pharma has commenced patient enrollment at Neurostudies, Inc. in Port Charlotte, Florida, for its Phase 2…
A leader in Personalized Therapy Decision Support and Precision Drug Development, Cellworks, has announced the opening of a CLIA-certified computational laboratory in Franklin, Tennessee. Administered by the Centers for Medicare…
Be Biopharma Announces FDA Clearance for BE-101 IND Application in Hemophilia B Be Biopharma, Inc. (“Be Bio”), a pioneer in Engineered B Cell Medicines (BCMs), has announced the U.S. Food…
A clinical-stage biotechnology company developing biologics to enhance regulatory T cell (Treg) function, Coya Therapeutics, has announced that MSCI has included its shares in the MSCI USA Micro Cap Index…
Integrated Biosciences, a biotechnology company leveraging synthetic biology and machine learning to create next-generation therapeutics for age-related diseases, announced its collaboration with Illumina Ventures Labs. This partnership aims to integrate…
The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Sarclisa (isatuximab) for Priority Review. The application is for the investigational use of Sarclisa…
A Journey from Curiosity About Life on Earth to Transformative Therapies at Novartis When I was young, my fascination with science began with the natural world and animals. A BBC…
High-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which previously met the primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) over docetaxel in patients…